Sattva Sukun Lifecare Ltd (539519)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 4 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 30 அக். 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Sattva Sukun Lifecare Ltd reported Q2 FY27 results on 4 Nov 2026: revenue ₹5.0 Cr (-70.1% year on year, +687.4% on the previous quarter), and net profit ₹-0.4 Cr (against a profit a year earlier); the operating margin was -13.9%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹5.0 | -70.1% | +687.4% |
| செயல்பாட்டு லாபம் | ₹-0.7 | நஷ்டமாக | நஷ்டம் அதிகரித்தது |
| நிகர லாபம் | ₹-0.4 | நஷ்டமாக | நஷ்டம் அதிகரித்தது |
| EPS (₹) | -0.01 | நஷ்டமாக | — |
| செயல்பாட்டு லாப வரம்பு | -13.9% | — | — |
- நஷ்டத்தில்: ஓராண்டுக்கு முன் லாபம்
- செயல்பாட்டு லாப வரம்பு 2078 bps YoY குறைந்தது
- லாபம் இருந்தும் FY26-இல் செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Tavexia Lifecare's Board has granted in-principle approval to raise up to ₹68 crore via preferential issue, rights issue, or other securities. The capital will fund its previously approved acquisition of a 60% stake in Meyonex Pharmaceuticals Limited. In comparison to TTM revenue of ₹32 crore and net worth of ₹43 crore, the proposed fundraise represents over 2x annual revenue and ~158% of net worth. Additionally, the company took on record its Q2 FY27 financial results and approved shifting its RTA to Skyline Financial Services.
- In-principle approval to raise up to ₹68,00,00,000 (₹68 crore) in one or more tranches
- Proceeds intended to finance the acquisition of 60% equity share capital of Meyonex Pharmaceuticals Limited
- Fundraise of ₹68 crore compares to TTM revenue of ₹32 crore and net worth of ₹43 crore
- Change in Registrar & Transfer Agent from Niche Technologies to Skyline Financial Services
- Fully utilized ₹19.16 crore raised through previous rights issue with zero deviation reported
Tavexia Lifecare Ltd's Board has granted in-principle approval to raise up to ₹68 crore in one or more tranches via preferential issue, rights issue, or other securities. The capital will fund its previously approved acquisition of a 60% equity stake in Meyonex Pharmaceuticals Limited. In comparison, the company reported TTM revenue of ₹32 crore and a net worth of ₹43 crore, making the planned fundraise over 2x TTM revenue. Additionally, the Board approved Q2 FY27 unaudited results and shifted its Registrar and Transfer Agent from Niche Technologies to Skyline Financial Services.
- In-principle approval to raise funds up to ₹68,00,00,000 (₹68 crore) via equity or other securities
- Proceeds intended to finance the acquisition of 60% equity share capital of Meyonex Pharmaceuticals Limited
- Fundraise size represents ~212% of the company's TTM revenue of ₹32 crore
- Approved transition of RTA from Niche Technologies Pvt. Ltd to Skyline Financial Services Pvt. Ltd
- Fully deployed earlier rights issue proceeds of ₹19.16 crore with zero reported deviation
Tavexia Lifecare has scheduled a Board of Directors meeting on November 4, 2026. The board will consider Q2 and H1 FY27 unaudited financial results and evaluate a proposal to raise funds via equity or warrants through a preferential or rights issue. In addition, the board will review a proposed change of the company's Registrar and Share Transfer Agent (RTA).
- Board meeting scheduled on November 4, 2026
- To review unaudited Standalone and Consolidated financial results for the quarter and half-year ended September 30, 2026
- To consider a proposal for raising funds through Equity/Warrants via Preferential or Rights issue
- To consider and approve the change of Registrar and Share Transfer Agent (RTA)
Tavexia Lifecare Limited has announced the acquisition of a 60% controlling equity stake in Meyonex Pharmaceuticals Limited for ₹67.19 Crore. The transaction will be executed via cash subscription of 2,09,97,180 fresh equity shares at ₹32 per share, granting Tavexia access to a manufacturing unit in MIDC Tarapur, Maharashtra. The ₹67.19 Crore transaction is massive relative to Tavexia's scale, exceeding 200% of its TTM revenue of ₹32 Crore and net worth of ₹43 Crore. To finance the purchase, the company plans to initiate strategic fund-raising via equity or convertible instruments.
- Acquiring a 60% controlling stake in Meyonex Pharmaceuticals Limited for ₹67.19 Crore
- Subscription of 2,09,97,180 fresh equity shares at an issue price of ₹32 per share
- Deal value represents ~210% of TTM revenue (₹32 Cr) and exceeds net worth (₹43 Cr)
- Target brings an operational manufacturing base in MIDC Tarapur, Maharashtra
- Financing planned via fresh strategic fund-raising through equity or convertible instruments
Tavexia Lifecare's Board approved the acquisition of a 60% controlling stake in Meyonex Pharmaceuticals Limited for an all-cash consideration of ₹67.19 crore. The transaction involves subscribing to 2,09,97,180 fresh equity shares of Meyonex at ₹32 per share. To finance this acquisition, which significantly exceeds Tavexia's TTM revenue of ₹32 crore and net worth of ₹43 crore, the Board approved an in-principle fundraise via equity, warrants, or debt. Meyonex reported a turnover of ₹10.79 crore in FY25.
- Proposed acquisition of 60% post-allotment equity stake (2,09,97,180 shares) in Meyonex Pharmaceuticals Limited
- Total cash consideration fixed at ₹67,19,09,760 at an issue price of ₹32 per share
- In-principle approval to raise funds via preferential issue, rights issue, or debt to fund the deal
- Target entity reported FY25 turnover of ₹10,79,21,500 compared to ₹13,32,07,500 in FY24
Tavexia Lifecare has scheduled a Board meeting on October 7, 2026, to deliberate on the proposed acquisition of up to 60% equity in Meyonex Pharmaceuticals Limited. This follows an initial approval granted on September 7, 2026, which authorised preliminary evaluation, valuation, and due diligence. For a micro-cap company with a market cap of approximately ₹1 crore and TTM revenue of ₹32 crore, acquiring a controlling stake could significantly alter its operational footprint. Additionally, the trading window has been closed from September 30, 2026, ahead of the half-year results.
- Board meeting scheduled for October 7, 2026, to discuss proposed acquisition
- Target is up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited
- Follows earlier board approval dated September 7, 2026, for due diligence and valuation
- Trading window closed from September 30, 2026, until 48 hours after H1 results
Tavexia Lifecare Limited has announced its strategic entry into the pharmaceutical business as an additional growth vertical alongside its existing lifecare operations. The company plans to explore opportunities across pharma products, APIs, intermediates, specialty chemicals, and nutraceuticals. However, the announcement does not disclose any concrete capex commitments, manufacturing locations, or commercial timelines. This comes against a micro-cap financial base with TTM revenue of ₹32 Cr and a market cap of ₹1 Cr.
- Announced entry into pharmaceuticals covering APIs, intermediates, specialty chemicals, and nutraceuticals
- Cites Indian pharma market size at ~US$60 billion, projected to reach ~US$130 billion by 2030
- Highlights Indian pharma exports at ~US$30.47 billion in FY2024-25
- Specific capital outlay and operational timelines were not disclosed in the filing
Sattva Sukun Lifecare Limited has received approval from the Ministry of Corporate Affairs (MCA) and BSE Limited to change its name to Tavexia Lifecare Limited. The Central Processing Centre of the MCA issued a fresh Certificate of Incorporation on August 14, 2026. The company operates in the distribution sector with a TTM revenue of Rs 32 Cr and a market capitalization of Rs 1 Cr. The name change is a corporate rebranding step and does not alter the company's underlying assets, liabilities, or business operations.
- Name changed from Sattva Sukun Lifecare Limited to Tavexia Lifecare Limited
- MCA issued fresh Certificate of Incorporation on August 14, 2026
- BSE Limited has approved the application for the corporate name change
- Original company incorporation name was Mayukh Commercial Limited under CIN L51219MH1980PLC329224
Sattva Sukun Lifecare approved its Q1 FY27 financial results and provided an update on its July 2025 Rights Issue. The company raised Rs 19.16 crore and has successfully utilized Rs 18.92 crore (approx. 98.7%) as of June 30, 2026. A significant portion of the funds, Rs 11.94 crore, was directed toward strategic investment in its subsidiary, PavaPuri Export Private Limited. Despite the large fund deployment, the company remains a micro-cap with a market capitalization of only Rs 1 crore and a low promoter holding of 6.4%.
- Raised Rs 19.16 crore through a Rights Issue completed on July 7, 2025
- Utilized Rs 18.92 crore of the total proceeds as of the quarter ended June 30, 2026
- Invested Rs 11.94 crore into subsidiary M/s PavaPuri Export Private Limited for strategic growth
- Allocated Rs 3.00 crore for business expansion, including acquisition of office premises, factory, and land
- Reported zero deviation in the use of funds compared to the modified objects of the issue
Sattva Sukun Lifecare (formerly Mayukh Dealtrade) approved its Q1 FY27 results and reviewed the utilization of Rs 19.16 Cr raised via a Rights Issue in July 2025. As of June 30, 2026, the company has deployed Rs 18.91 Cr, representing 98.7% of the total funds raised. A significant portion of the proceeds, Rs 11.94 Cr, was directed toward a strategic investment in its subsidiary, PavaPuri Export Private Limited, while Rs 3.00 Cr was used for business expansion including office and factory premises.
- Rs 19.16 Cr total funds raised via Rights Issue on July 7, 2025.
- Rs 18.91 Cr total funds utilized as of June 30, 2026, leaving a balance of Rs 0.24 Cr.
- Rs 11.94 Cr invested in subsidiary M/s PavaPuri Export Private Limited, the largest single allocation.
- Rs 3.00 Cr deployed for business expansion including acquisition of office premises, factory, and land.
- Original fund-raising target of Rs 49.50 Cr was significantly scaled down to Rs 19.16 Cr.
Sattva Sukun Lifecare (formerly Mayukh Dealtrade) has scheduled a board meeting for August 4, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. Crucially, the board will also review the statement of deviation or variation regarding the use of proceeds from its Rights Issue. This comes as the company reported a significant revenue jump to Rs 32.25 Cr in FY26 but struggled with a negative operating margin of -15.91%. Investors should remain cautious given the company's micro-cap status (Rs 1 Cr) and low promoter holding of 6.39%.
- Board meeting scheduled for August 4, 2026, to approve Q1 FY27 results.
- Review of fund utilization from the Rights Issue as per Regulation 32 of SEBI LODR.
- Trading window for designated persons has been closed since April 1, 2026.
- Company reported TTM revenue of Rs 32 Cr against a tiny market cap of just Rs 1 Cr.
- Promoter holding remains stagnant and low at 6.39% as of June 2026.
Sattva Sukun Lifecare Ltd has issued a corrigendum to its Extra-Ordinary General Meeting (EOGM) notice scheduled for July 22, 2026. The primary agenda is to change the company's name to Tavexia Lifecare Limited for branding purposes. The corrigendum includes a required Chartered Accountant certificate confirming compliance with SEBI Regulation 45, noting that more than one year has passed since the previous name change on December 12, 2024. The company maintains that its core business in lifecare and wellness remains unchanged.
- Proposed name change from Sattva Sukun Lifecare Limited to Tavexia Lifecare Limited
- EOGM scheduled for July 22, 2026, at 02:00 PM via video conferencing
- Last name change from Mayukh Dealtrade Limited occurred on December 12, 2024
- Corrigendum issued to address BSE queries regarding the in-principle application for name change
- Company confirms no change in principal business activity or legal status
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
